A PHASE II STUDY OF PEMBROLIZUMAB AND DYNAMIC PD-L1 EXPRESSION IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC)
Brief description of study
If you have small cell lung cancer and are untreated or have started initial treatment without recurrence, you may be eligible for this study. The primary goal of the study is to evaluate the impact of standard chemotherapy and radiation on the immune cells around the tumor and to assess the impact of adding a PD-1 inhibitor, pembrolizumab, to standard therapy at different times during the course of initial treatment.
1--Two groups of subjects will receive pembrolizumab with chemotherapy (either from the beginning or after one cycle of therapy)
2- Two groups of subjects will receive pembrolizumab AFTER initial chemotherapy (either with or without radiation)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.